Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Search bilingual publication guides on delivery, in vivo CAR-T, therapeutic translation, safety, analytics, and manufacturing.
A GEN commentary by a USP principal scientist argues that mRNA development is shifting toward precision delivery across cancer, protein replacement, encoded antibodies, regenerative medicine, and gene editing. It emphasizes reaching appropriate tissues and cell types while limiting unintended exposure. This is an industry perspective on development priorities, not a new clinical readout.
Circular RNA nanoparticles encoding the malaria transmission antigen Pvs25 were compared with a modified linear mRNA vaccine in mice. Both platforms induced antigen-specific responses, and booster immunization generated antibodies that blocked parasite development in mosquito assays. The findings support further evaluation of circular RNA for transmission-blocking vaccination, without establishing greater efficacy, durability, or manufacturing economy than linear mRNA in humans.
Sensible announced a $47 million financing package comprising an Oxford Science Enterprises-led Series A and up to $20 million in non-dilutive funding. Transaction adviser DLA Piper confirmed that proceeds will support VECTOR platform scale-up, AI-enabled sequence design, high-throughput screening, and clinical-grade manufacturing capabilities. The $47 million figure is not a disclosed equity-only round size.
Screening eight ionizable lipids identified a lead formulation that delivered reporter RNA to several immune-cell types. Researchers then used it to engineer primary human T cells expressing a MUC1-directed CAR, with cytotoxic activity against antigen-positive tumor cells in vitro. Animal reporter experiments supported delivery feasibility, but the study does not demonstrate therapeutic CAR-T generation inside patients or animals.
Synthego and Biomay announced a nonexclusive North American marketing and resale collaboration covering CRISPR components and manufacturing services. The offering combines Synthego guide RNA expertise with Biomay’s Cas9, mRNA manufacturing, LNP formulation, and aseptic fill-finish capabilities, including research and cGMP options. This is a commercial supply collaboration rather than a new factory opening or a new medicine approval.
Bio Farma selected Quantoom’s Ntensify platform for Indonesian mRNA vaccine development and completed an initial RNA production run in Bandung using a rabies DNA template. Quantoom reported that the 200 mL in vitro transcription run met predefined criteria. CEPI partly supported platform installation. The milestone concerns manufacturing capability building, not demonstrated vaccine efficacy or authorization for commercial product release.
This review evaluates electrophoresis, chromatography, sequencing, and mass spectrometry for measuring mRNA drug-substance identity, length, concentration, intactness, and purity. It compares throughput, sample preparation, and total analysis time while considering multi-attribute methods used for protein therapeutics. The authors identify opportunities for integrated mRNA analytics, rather than validating a universal platform that replaces all individual quality assays.
4basebio announced clinical-grade enzymatic opDNA starting-material supply for an unnamed multinational pharmaceutical company’s cell therapy program. TriLink was selected as the mRNA development and manufacturing partner, using its CleanCap technology. The collaboration supports an upcoming Phase I program and illustrates coordination between DNA template and mRNA suppliers. The customer and financial terms were undisclosed; no clinical outcomes were reported.
The AGENT platform combines Bayesian optimization with high-throughput experiments to identify thermostable mRNA-LNP formulations through six iterations in approximately one month. Solid-state model formulations based on SM-102 and ALC-0315 retained biological activity after more than two months at 37°C. Animal immunogenicity supported further development, but these formulation-specific findings do not eliminate cold-chain requirements for mRNA products generally.
Using a common ALC-0315 formulation, the study compared reporter expression from conventional mRNA, self-amplifying RNA, and plasmid DNA, individually and in combinations. Mouse experiments showed distinct timing and duration associated with payload identity. Mixed preparations generally behaved additively under the tested conditions. The work helps separate cargo effects from formulation effects, without establishing universal expression profiles across doses, tissues, or products.
Investigators administered nanoparticles to several gastrointestinal submucosal sites to examine route-dependent targeting. Gastric delivery increased pancreatic exposure in rodents, while GLP-1 mRNA improved glucose regulation in mice. Buccal administration supported local and lymphatic targeting with vaccine responses. These are tissue-directed administration experiments; they do not establish that conventional swallowed nanoparticles can survive digestion and reproduce the same delivery profile.
A lipid screen explicitly incorporated a large base-editor transcript rather than relying on small reporter RNA. The lead lipid retained favorable RNA interactions and membrane-disrupting structure as cargo size increased. It improved editing in liver, brain, and lung using different administration routes, including intrathecal and intratracheal dosing. The findings do not establish systemic delivery to all three organs.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
